The latest on CAR-T cell therapy in China — approvals, international patient journeys, and the science of living drugs.
Engineered retrotransposons delivered as RNA via LNP reprogram T cells inside the body — no virus, no ex vivo manufacturing.
Read article →A real-world cohort finds CD5 positivity is an independent adverse marker for CD19 CAR-T — with a sharp warning for patients progressing at infusion.
Read article →From four generations of engineering to the three ways CAR-T cells destroy tumors — a clear, plain-language guide.
Read article →How an international patient with refractory diffuse large B-cell lymphoma reached a CAR-T program in China after multiple relapses.
Read story →From the first NMPA-approved CAR-T in 2021 to a fast-expanding pipeline — what international patients can access today.
Read article →Why solid tumors are harder for CAR-T — and how targets like Claudin18.2 and GPC3 are opening new fronts.
Read article →The hospitals we work with publish their own CAR-T case reports, trial notices and research updates. Here are four of the latest, in their own words — 31 articles in all, from 8 centres.
Twenty-three children with relapsed or refractory T-ALL went from CD7 CAR-T straight into allogeneic transplant; 84.8% were relapse-free at two years.
Patient storyJosh went home on 16 August after more than a month of treatment — the first international patient to finish CT041 therapy at Jiahui.
Patient storyA 53-year-old with gastric cancer and peritoneal spread saw his PCI score fall from 9 to 0 within eight months, then reached surgery — still controlled at 48 months.
CAR-TAfter a CD20 CAR-T and then a CD19/PD1/CD28 CAR-T both failed, a stepwise bispecific sequence brought refractory DLBCL back under control.